Furthermore, SMG1 inhibitors might be effective in other malignancies that depend on the UPR for survival such as Waldenström's macroglobulinemia, acute myeloid leukemia (AML), as well as other solid tumor types. This evidence concerns the gene SMG1 and acute myeloid leukemia.